WallStSmart

America Movil SAB de CV ADR (AMX)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

America Movil SAB de CV ADR generates 14946% more annual revenue ($948.44B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 9.2%. AMX appears more attractively valued with a PEG of 1.18. AMX earns a higher WallStSmart Score of 65/100 (C+).

AMX

Buy

65

out of 100

Grade: C+

Growth: 5.3Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 1.37

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMX.

EWUndervalued (+69.7%)

Margin of Safety

+69.7%

Fair Value

$261.90

Current Price

$79.96

$181.94 discount

UndervaluedFair: $261.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMX6 strengths · Avg: 8.3/10
Market CapQuality
$80.46B9/10

Large-cap with strong market position

Return on EquityProfitability
21.1%9/10

Every $100 of equity generates 21 in profit

P/E RatioValuation
16.0x8/10

Attractively priced relative to earnings

Operating MarginProfitability
21.3%8/10

Strong operational efficiency at 21.3%

EPS GrowthGrowth
25.8%8/10

Earnings expanding 25.8% YoY

Free Cash FlowQuality
$3.27B8/10

Generating 3.3B in free cash flow

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

AMX3 concerns · Avg: 2.3/10
Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Altman Z-ScoreHealth
1.372/10

Distress zone — elevated risk

Debt/EquityHealth
2.531/10

Elevated debt levels

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : AMX

The strongest argument for AMX centers on Market Cap, Return on Equity, P/E Ratio. PEG of 1.18 suggests the stock is reasonably priced for its growth.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : AMX

The primary concerns for AMX are Revenue Growth, Altman Z-Score, Debt/Equity. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.

Key Dynamics to Monitor

AMX profiles as a value stock while EW is a growth play — different risk/reward profiles.

EW carries more volatility with a beta of 0.87 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

AMX generates stronger free cash flow (3.3B), providing more financial flexibility.

Bottom Line

AMX scores higher overall (65/100 vs 61/100). EW offers better value entry with a 69.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

America Movil SAB de CV ADR

COMMUNICATION SERVICES · TELECOM SERVICES · USA

Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?